Publication date
Downloads
The publication 'Bone and soft tissue tumour epidemiology in Belgium, 2004-2019', produced with the support of Stichting tegen Kanker (Foundation against Cancer), describes for the first time the epidemiology of bone and soft tissue tumours in Belgium over a 15-year period (2004–2019).Bone and soft tissue tumours are a very heterogeneous, complex and rare group of tumours (about 1,175 new diagnoses a year) with some subtypes being diagnosed only a few times a year. Compared with other types of cancer, relatively more children, adolescents and young adults are affected. This report describes incidence, prevalence, survival and trends over the period, as well as incidence projections to 2030 – always as a function of primary tumour location (soft tissue versus bone) and histological tumour subtype.
Bone and soft tissue tumours are a very heterogeneous, complex and rare group of tumours (about 1,175 new diagnoses a year) with some subtypes being diagnosed only a few times a year. Compared with other types of cancer, relatively more children, adolescents and young adults are affected. This report describes incidence, prevalence, survival and trends over the period, as well as incidence projections to 2030 – always as a function of primary tumour location (soft tissue versus bone) and histological tumour subtype.
An increase of 0.6% a year is expected in the risk of bone and soft tissue tumours. The rarity and heterogeneity of this group of tumours poses a challenge for patient care. On the positive side, survival for these types of tumours has increased over the past 15 years, particularly in patients aged 40 or older.
Bone and soft tissue tumours are a very heterogeneous, complex and rare group of tumours (about 1,175 new diagnoses a year) with some subtypes being diagnosed only a few times a year. Compared with other types of cancer, relatively more children, adolescents and young adults are affected. This report describes incidence, prevalence, survival and trends over the period, as well as incidence projections to 2030 – always as a function of primary tumour location (soft tissue versus bone) and histological tumour subtype.
An increase of 0.6% a year is expected in the risk of bone and soft tissue tumours. The rarity and heterogeneity of this group of tumours poses a challenge for patient care. On the positive side, survival for these types of tumours has increased over the past 15 years, particularly in patients aged 40 or older.